Adage Capital Partners Gp, L.L.C. Tarsus Pharmaceuticals, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $51.6 Billion
- Q1 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 510,000 shares of TARS stock, worth $21.2 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
510,000Holding current value
$21.2 Million% of portfolio
0.05%Shares
1 transactions
Others Institutions Holding TARS
# of Institutions
199Shares Held
44.1MCall Options Held
19.9KPut Options Held
7.6K-
Rtw Investments, LP New York, NY3.32MShares$138 Million2.79% of portfolio
-
Black Rock Inc. New York, NY3.27MShares$136 Million0.0% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.61MShares$108 Million6.87% of portfolio
-
Jennison Associates LLC2.49MShares$103 Million0.09% of portfolio
-
Tang Capital Management LLC San Diego, CA2.45MShares$102 Million8.19% of portfolio
About Tarsus Pharmaceuticals, Inc.
- Ticker TARS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,658,500
- Market Cap $1.11B
- Description
- Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...